SSA
CATX icon

Schonfeld Strategic Advisors’s Perspective Therapeutics CATX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,370
Closed -$172K – 2267
2025
Q4 		$172K Buy
+62,370
New +$178K ﹤0.01% 1744
2025
Q3 		– Sell
-143,332
Closed -$493K – 2233
2025
Q2 		$493K Buy
+143,332
New +$378K ﹤0.01% 1546
2025
Q1 		– Sell
-168,500
Closed -$538K – 2223
2024
Q4 		$538K Sell
168,500
-423,123
-72% -$3.45M ﹤0.01% 1357
2024
Q3 		$7.9M Buy
591,623
+65,823
+13% +$875K 0.05% 370
2024
Q2 		$5.24M Buy
525,800
+242,760
+86% +$3.51M 0.03% 534
2024
Q1 		$3.37M Buy
+283,040
New +$2.41M 0.02% 790

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's CATX Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 62,370 shares — an estimated $172K sold.

Schonfeld Strategic Advisors first reported a position in CATX in Q1 2024 and held it in 6 quarters. The position peaked at $7.9M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 62,370 Perspective Therapeutics shares in Q1 2026, an estimated $172K.
  • Schonfeld Strategic Advisors first reported a position in Perspective Therapeutics in Q1 2024 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Perspective Therapeutics position peaked at $7.9M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.